Double layered self-expanding metal stents for malignant esophageal obstruction, especially across the gastroesophageal junction

Min Dae Kim, Su Bum Park, Dae Hwan Kang, Jae Hyung Lee, Cheol Woong Choi, Hyung Wook Kim, Chung Uk Chung, Young Il Jeong

Min Dae Kim, Jae Hyung Lee, Department of Internal Medicine, Bongseng Memorial Hospital, Busan 601-723, South Korea Su Bum Park, Dae Hwan Kang, Cheol Woong Choi, Hyung Wook Kim, Chung Uk Chung, Young Il Jeong, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan 626-770, South Korea

Author contributions: Kim MD and Park SB contributed equally to this work; Kim MD, Park SB and Kang DH designed the research; Kim MD, Park SB, Kang DH, Lee JH, Choi CW, Kim HW, Chung CU and Jeong YI performed the research; Kim HW and Choi CW analyzed the data; and Kim MD and Park SB wrote the paper.

Supported by A grant from the Korea Healthcare Technology R and D Project, Ministry for Health, Welfare and Family Affairs, South Korea, No. A091047

Correspondence to: Dae Hwan Kang, PhD, MD, Department of Internal Medicine, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Beomeo-ri, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do, Yangsan 626-770, South Korea. sulsupul@yahoo.co.kr
Telephone: +82-55-3601535 Fax: +82-55-3601536
Received: December 5, 2011 Revised: February 1, 2012
Accepted: April 13, 2012
Published online: July 28, 2012

Abstract

AIM: To evaluate the clinical outcomes of double-layered self-expanding metal stents (SEMS) for treatment of malignant esophageal obstruction according to whether SEMS crosses the gastroesophageal junction (GEJ).

METHODS: Forty eight patients who underwent the SEMS insertion for malignant esophageal obstruction were enrolled. Patients were classified as GEJ group (SEMS across GEJ, 18 patients) and non-GEJ group (SEMS above GEJ, 30 patients) according to SEMS position. Double layered (outer uncovered and inner covered stent) esophageal stents were placed.

RESULTS: The SEMS insertion and the clinical improvement were achieved in all patients in both groups. Stent malfunction occurred in seven patients in the GEJ group and nine patients in the non-GEJ group. Tumor overgrowth occurred in five and eight patients, respectively, food impaction occurred in one patient in each group, and stent migration occurred in one and no patient, respectively. There were no significant differences between the two groups. Reflux esophagitis occurred more frequently in the GEJ group (eight vs five patients, $P = 0.036$) and was controlled by proton pump inhibitor. Aspiration pneumonia occurred in zero and five patients, respectively, and tracheoesophageal fistula occurred in zero and two patients, respectively.

CONCLUSION: Double-layered SEMS are a feasible and effective treatment when placed across the GEJ for malignant esophageal obstruction. Double-layered SEMS provide acceptable complications, especially migration, although reflux esophagitis is more common in the GEJ group.

© 2012 Baishideng. All rights reserved.

Key words: Metal stent; Gastroesophageal junction; Malignant esophageal obstruction

Peer reviewers: Jens Hoeppner, Assistant Professor, MD, Department for General and Visceral Surgery, Universitaetsklinikum Freiburg, Hugstetterstr. 55, 79106 Freiburg, Germany; Satoru Motoyama, MD, PhD, Department of Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; Liang-Shun Wang, Professor, Vice-superinten-
INTRODUCTION

Despite recent developments in diagnosis and treatment, more than 50% of malignancies involving the esophagus are inoperable and the 5-year survival rates are < 10% at present.[1,2] In advanced or metastatic patients, therapy is usually palliative in nature, with the major aims being relief of dysphagia, maintenance of nutrition, or closure of the tracheoesophageal fistula. Self-expanding metal stents (SEMS) are widely used for the relief of patients with dysphagia, providing rapid, safe, and effective symptomatic relief in most patients[3-6]. However, placing a stent across the gastroesophageal junction (GEJ) faces several limitations due to anatomical features leading to a higher migration rate and gastroesophageal reflux[7-10].

Covered stents are now the most commonly used type in esophageal obstruction to prevent tumor ingrowth. But, covered stents are more likely to migrate than uncovered stents, especially in the region of the GEJ. Therefore, uncovered stents should be considered to prevent migration in those cases. However, considering the risk of stent obstruction owing to tumor in-growth and stent migration in GEJ tumors, a newly designed stent with advantages of uncovered (low migration rate) and covered (low tumor in-growth) stents should be considered.[11-13]

Although several studies have reported the efficacy of SEMS in malignant esophageal obstruction, there are only limited data about stenting across the GEJ.[14-16] Because placement of SEMS across the GEJ has a tendency of higher migration, we evaluated the clinical outcomes of double-layered SEMS for treatment of malignant esophageal obstruction according to whether SEMS crossed the GEJ.

MATERIALS AND METHODS

Patients

Between February 2005 and June 2010, we enrolled a consecutive series of 48 patients with malignant esophageal obstruction who underwent SEMS placement. All patients had pathologically proven esophageal or gastric cardiac carcinoma. None were candidates for curative surgical treatment because of advanced or metastatic disease or poor functional status. Informed consent for stent placement was obtained from each patient before SEMS placement.

SEMS construction and placement

Double-layered stent (Niti-S double layered esophageal stent; Taewoong, Seoul, South Korea) was used throughout the study. The double-layered stent was designed to have the advantages of both uncovered (low migration rate) and covered (low tumor ingrowth) stents to resolve some of the disadvantages of pre-existing metal stents. The stents consist of an inner polyurethane membrane covered stent to prevent tumor ingrowth and an outer uncovered nitinol wire to reduce migration. The outer uncovered stent overlapped in the central portion of the covered stent (Figure 1). Because there is space between the covered and uncovered stent in the central portion, this space permits tissue and tumor growth throughout. Thus, the double-layered stent becomes anchored to the esophageal wall.

Patients were consciously sedated with intravenous midazolam during the procedure. Under fluoroscopic and endoscopic visualization, the length of the stricture was measured. A stent 2-4 cm longer than the length of the stricture was chosen to allow for a 1-2 cm extension above and below the proximal and distal tumor margin, respectively. After the guidewire was inserted through the stricture, the delivery system of the stent was gently introduced. After the stent placement, the positioning of the stent was assessed both radiographically and endoscopically.
Assessment of clinical outcomes and complications

The technical success of stent placement was defined as adequate positioning and deployment of the stent with complete bridging of the stricture. For the assessment of clinical improvement, we used a dysphagia score: score 0, ability to eat a normal diet; score 1, ability to eat some solid food; score 2, ability to eat some semisolids only; score 3, ability to swallow liquids only; score 4, complete inability to swallow[11]. This was measured before and 1-2 weeks after the stent placement. We evaluated stent malfunction due to tumor overgrowth, stent migration, or food impaction and other complications including reflux esophagitis, aspiration pneumonia, or fistula.

Statistical analysis

Differences between categorical variables were examined statistically using the $\chi^2$ test. Dysphagia scores before and after the stent placements were analyzed by the paired-t test. The incidence of complications was compared between two groups using the $\chi^2$ test. All statistical analyses were performed with SPSS 12.0 (SPSS, Chicago, IL). A P value < 0.05 was considered statistically significant.

RESULTS

The clinical characteristics of the patients are shown in Table 1. Forty eight patients (39 men, mean age 68.4 years, range 45-86 years) with esophageal obstruction underwent SEMS placement. The histological types were squamous cell carcinoma in 32 patients (66.6%) and adenocarcinoma in 16 (33.4%). The location of obstruction was in the GEJ in 18 patients (37.5%) and non-GEJ in 30 patients (62.5%). In our study, GEJ obstruction meant that the location of obstruction was in the far distal esophagus and GEJ. Non-GEJ obstruction meant that the location of obstruction were in the upper, middle, and proximal distal esophagus. Before stent placement, 39.6% (19/48) of patients received anticancer treatments such as chemoradiotherapy ($n = 11$, 22.9%), radiation therapy ($n = 7$, 14.6%) or chemoradiation therapy ($n = 1$, 2.1%). The remaining ($n = 29$, 60.4%) patients received supportive care. Patients were classified as GEJ (18 patients including distal esophageal cancer and GEJ cancer patients) and non-GEJ groups (30 patients) according to SEMS position. In GEJ group, SEMS placed across GEJ and distal flange portion of SEMS did not anchor to the esophageal wall but was free in the cardia portion. Baseline characteristics are similar except for histologic types.

The placement of esophageal stents was technically successful in all patients. Clinical success rates for malignant esophageal obstruction were 100%. The mean dysphagia score improved from 3.20 ± 0.68 to 1.77 ± 0.77 ($P < 0.001$) by stent placement. The mean dysphagia score improved from 3.05 ± 0.63 to 1.77 ± 0.73 ($P < 0.001$) and 3.30 ± 0.70 to 1.76 ± 0.81 ($P < 0.001$) in GEJ obstruction and in non-GEJ obstruction, respectively (Table 2). Most patients complained of mild foreign body sensation or pain immediately after the stent placement and were getting better and free of these symptoms after several days. There was no procedure-related mortality within 24 h of the intervention.

Stent malfunctions developed in 16 (33.3%) patients [seven (38.9%) for GEJ group and nine (30.0%) for non-GEJ group], the causes of which consisted of tumor overgrowth (13 patients, 27%), stent migration (one patient, 2.1%) and food impaction (two patients, 4.2%). Tumor overgrowth, stent migration, and food impaction occurred in five (27.8%) and eight (26.7%) patients, zero (5.6%) and zero patient, and one (5.6%) and one (3.3%) patient in the GEJ and non-GEJ obstruction, respectively (Table 3). There was no significant difference between GEJ and non-GEJ groups.

Twenty patients (41.6%) showed complications such as reflux esophagitis (13 patients, 27.1%), aspiration pneumonia (five patients, 10.4%), and tracheoesophageal fistula (two patients, 4.2%). Only reflux esophagitis occurred more frequently in GEJ group [eight (44.4%) v five (16.7%), $P = 0.036$]. Aspiration pneumonia and tracheoesophageal fistula occurred in zero and five (16.7%) and zero and two (6.7%) patients in the GEJ and non-GEJ obstruction, respectively.

### Table 1 Patient baseline characteristics ($n = 48$) $n$ (%)

|                | Overall ($n = 48$) | GEJ obstruction ($n = 18$) | Non-GEJ obstruction ($n = 30$) | $P$ value |
|----------------|-------------------|---------------------------|-------------------------------|-----------|
| Age (yr, mean ± SD) | 68.4 ± 10.5       | 65.8 ± 10.3               | 69 ± 10.5                     | 0.749     |
| Male            | 39 (81.3)         | 12 (25.0)                 | 27 (54.2)                     | 0.045     |
| Histological diagnosis |          |                           |                               |           |
| Squamous cell carcinoma | 32 (66.6) | 2                          | 30                             | 0.001     |
| Adenocarcinoma   | 16 (33.4)         | 16                         | 0                              | 0.001     |
| Type of treatment before SEMS placement |          |                           |                               |           |
| Supportive care  | 29 (60.4)         | 10                         | 19                             | 0.594     |
| Chemotherapy     | 11 (22.9)         | 7                          | 4                              | 0.041     |
| Radiation therapy| 7 (14.6)          | 1                          | 6                              | 0.170     |
| Chemoradiation therapy | 1 (2.1) | 0                          | 1                              | 0.434     |

GEJ obstruction, distal esophageal and gastroesophageal junction obstruction; Non-GEJ obstruction, middle and upper esophageal obstruction. GEJ: Gastroesophageal junction.

### Table 2 Clinical outcomes in 48 patients $n$ (%)

| Outcomes                  | Overall ($n = 48$) | GEJ obstruction ($n = 18$) | Non-GEJ obstruction ($n = 30$) | $P$ value |
|---------------------------|-------------------|---------------------------|-------------------------------|-----------|
| Technical success         | 48 (100)          | 18 (100)                  | 30 (100)                      |           |
| Clinical success          | 48 (100)          | 18 (100)                  | 30 (100)                      |           |
| Mean dysphagia score      | 3.20 ± 0.68       | 3.05 ± 0.63               | 3.30 ± 0.70                   |           |
| preprocedure (mean ± SD)  |                  |                           |                               |           |
| Mean dysphagia score      | 1.77 ± 0.77       | 1.77 ± 0.73               | 1.76 ± 0.81                   |           |
| postprocedure (mean ± SD) |                  |                           |                               |           |
| Change dysphagia score    | <0.001            | <0.001                    | <0.001                        |           |
| (paired-t test) ($P$ value) |                 |                           |                               |           |

GEJ obstruction, distal esophageal and gastroesophageal junction obstruction; Non-GEJ obstruction, middle and upper esophageal obstruction. GEJ: Gastroesophageal junction.
uncovered nitinol wire to allow the mesh of the stent to consist of an inner silicone membrane layer and an outer flares to 24-28 mm at both ends; this size was chosen to This device combines two specific characteristics. First, it may play a role in reducing migration. The double layered stent was designed to reduce stent migration (Figure 1). Second, it has a double-layered configuration, confirming the mesh to the gastric fundus without fixation to the esophageal or gastric wall. Furthermore, inner covered stent resists to tumor in-growth. So, double layered SEMS placement in GEJ is effective for prevention of stent migration with advantage of covered stent. Overall 27% of patients experienced a symptomatic reflux esophagitis, which is similar to incidence of other studies (27%) [9,10]. Placement of the stent across the GEJ eliminates the sphincter function of esophagus and permits free reflux of gastric contents into esophagus. Patients experience reflux from an increase in intraabdominal pressure and also passive reflux when gravity is eliminated [21]. Thus, stenting across the GEJ seems to lead gastroesophageal reflux and even aspiration pneumonia. Weston et al [24] reported gastroesophageal reflux disease, including cases of aspiration and death, in 27% of patients who had SEMS placed across the GEJ. Valbuena also reported cases of heartburn and coughing spells in 27% of patients in whom a standard open stent was used for palliative treatment of GEJ cancer [25]. It is widely known that reflux esophagitis is more common in westerners than Asians. But, in our study, reflux esophagitis (44.4%) was more frequent developed by SEMS insertion in GEJ obstruction, compared to other studies (27%). Because our study was retrospective in nature, reflux esophagitis might be overestimated and multiple post-procedure symptoms could be considered as reflux esophagitis symptoms. For example, not only heartburn and regurgitation, but also chest pain and epigastric pain could be regarded as reflux esophagitis symptoms. Asians complain of atypical reflux esophagitis symptoms more frequently than westerners [26] and 30% of atypical reflux esophagitis symptoms are related chest pain and epigastric pain [27].

As reported on another study [28], proton pump inhibitors were effective for controlling gastroesophageal reflux disease symptoms in most cases. Although several anti-reflux stents have been developed to prevent reflux, the results are conflicting [29,31]. These stents also have demerits of higher rates of migration and gas bloating after meals [32]. As our and Sabharwal et al [33] results, conventional SEMS placement with a proton pump inhibitor seems to be useful alternative to manage reflux in patients with stenting across GEJ. Our study has several limitations. First, since our study was a retrospective study, bias in evaluation of reflux esophagitis might be involved. Second, we did not take into consideration of anticancer treatment including chemotherapy and/or radiation therapy before SEMS placement. It is possible that these may cause different clinical outcomes in stent patency according to the oncologic outcomes of anticancer treatments. Consequently, such differences might have affected results of our study.

In conclusion, double-layered SEMS are feasible and seems to be associated with outer uncovered stent portion. A central uncovered stent makes space between the uncovered and covered stent in the central portion of double layered SEMS. Adjacent tumor or normal tissue invades through mesh and anchor SEMS firmly to the esophageal wall. Furthermore, inner covered stent resists to tumor in-growth. So, double layered SEMS placement in GEJ is effective for prevention of stent migration with advantage of covered stent.

### DISCUSSION

Given the increased incidence of carcinoma involving the distal esophagus and gastric cardia, SEMS are increasingly being deployed across the gastroesophageal junction. Although endoscopic placement of SEMS has become an easy and safe palliative treatment for malignant esophageal obstructions, placing a stent across the GEJ still has several problems associated with anatomic location, such as stent migration and reflux esophagitis [9,10]. However, little data has been published focusing on esophageal stenting across the GEJ.

In the present study, SEMS were shown to be a safe and effective treatment for malignant GEJ obstruction, providing a technical and clinical success rate of 100% and no procedure-related major complications. In comparison to another study [18], our technical and clinical success rate was similar.

Stent placement in GEJ is especially vulnerable to migration, because the distal portion of the stent projects freely into the gastric fundus without fixation to the esophageal or gastric wall [9]. In other studies, migration rates for covered stents have varied considerably, from 7% to as high as 50% [18,22]. Especially, migration rates for covered stent placement in GEJ was reported as 20% [20]. But, another study of migration rates for double layered stent placement in GEJ was reported as 4.7% [11]. In our study, stent migration developed in one (5.6%) patient in the GEJ group. It has been recognized that stent design may play a role in reducing migration. The double layered stent was designed to reduce stent migration (Figure 1). This device combines two specific characteristics. First, it flares to 24-28 mm at both ends; this size was chosen to minimize the risk of stent-related esophageal complications. Second, it has a double-layered configuration, consisting of an inner silicone membrane layer and an outer uncovered nitinol wire to allow the mesh of the stent to embed itself in esophageal wall. So, our low migration

| Causes of stent malfunctions | Overall (n = 48) | GEJ obstruction (n = 18) | Non-GEJ obstruction (n = 30) | P value |
|------------------------------|------------------|------------------------|-----------------------------|---------|
| Overgrowth                   | 13 (27.1)        | 5 (27.8)               | 8 (26.7)                    | 0.933   |
| Migration                    | 1 (2.1)          | 1 (5.6)                | 0 (0.0)                     | 0.192   |
| Food impaction               | 2 (4.2)          | 1 (5.6)                | 1 (3.3)                     | 0.709   |
| Other complications          |                  |                       |                             |         |
| Reflux esophagitis           | 13 (27.1)        | 8 (44.4)               | 5 (16.7)                    | 0.036   |
| Aspiration pneumonia         | 5 (10.4)         | 0 (0.0)                | 5 (16.7)                    | 0.067   |
| Fistula                      | 2 (4.2)          | 0 (0.0)                | 2 (6.7)                     | 0.263   |

GEJ: Gastroesophageal junction.

*Table 3 Complications and causes of stent malfunctions (n = 48)*
effective treatment when placing SEMS across GEJ for malignant esophageal obstruction. Double-layered SEMS provide acceptable complications, especially migration, although reflux esophagitis is more common in GEJ group.

**COMMENTS**

**Background**
There is not yet few data focusing esophageal stenting across gastroesophageal junction (GEJ). Because placement of self-expanding metal stents (SEMS) across the GEJ has a tendency of higher migration, the authors evaluated the clinical outcomes of double-layered SEMS for treatment of malignant esophageal obstruction according to whether SEMS across gastroesophageal junction.

**Research frontiers**
Placing a stent across the GEJ have several limitations due to anatomic features leading to a higher migration rate and gastroesophageal reflux. Double-layered SEMS provide acceptable complications, especially migration, although reflux esophagitis is more common in GEJ group.

**Innovations and breakthroughs**
The double-layered stent has the advantages of both uncovered (low migration rate) and covered (low in-growth rate) stents. The authors demonstrated the effectiveness of double-layered SEMS for treatment of malignant esophageal obstruction.

**Applications**
Double-layered SEMS are feasible and effective treatment when placing SEMS across GEJ for malignant esophageal obstruction.

**Terminology**
Double layered SEMS means that the stent consists of an outer uncovered and an inner covered stent. Dysphagia score is defined as follows: score 0, ability to eat a normal diet; 1, ability to eat some solid food; 2, ability to eat some semisolids only; 3, ability to swallow liquids only; and 4, complete inability to swallow.

**Peer review**
The paper is well structured and the results are presented and discussed in a good way.

**REFERENCES**

1. Stein HJ, Siewert JR. Improved prognosis of resected esophageal cancer. *World J Surg* 2004; 28: 520-525
2. Blot WJ. Esophageal cancer trends and risk factors. *Semin Oncol* 1994; 21: 403-410
3. Knyrim K, Wagner HJ, Bethge N, Kemyling M, Vakil N. A controlled trial of an expandable metal stent for palliation of esophageal obstruction due to inoperable cancer. *N Engl J Med* 1993; 329: 1302-1307
4. Ell C, May A. Self-expanding metal stents for palliation of stenosing tumors of the esophagus and cardia: a critical review. *Endoscopy* 1997; 29: 392-398
5. Rajiman I, Siddique I, Ajani J, Lynch P. Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. *Gastrointest Endosc* 1998; 48: 172-179
6. Baron TH, Schoff R, Fuespoak A, Sakai Y. Expandable metal stent placement for gastric outlet obstruction. *Endoscopy* 2001; 33: 623-628
7. Spinelli P, Cerri FA, Civilli M, Ignomirioli O, Meroni E, Pizzetti P. Endoscopic stent placement for cancer of the lower esophagus and gastric cardia. *Gastrointest Endosc* 1994; 40: 455-457
8. Bartelsman JF, Bruno MJ, Jensema AJ, Haringsma J, Reenders JW, Tytgat GN. Palliation of patients with esophagogastric neoplasms by insertion of a covered expandable modified Gianturco-Z endoprosthesis: experiences in 153 patients. *Gastrointest Endosc* 2000; 51: 134-138
9. Siersema PD, Marcon N, Vakil N. Metal stents for tumors of the distal esophagus and gastric cardia. *Endoscopy* 2003; 35: 79-85
10. Song HY, Do YS, Han YM, Sung KB, Choi EK, Sohn KH, Kim HR, Kim SH, Min YI. Covered, expandable esophageal metallic stent tubes: experiences in 119 patients. *Radiology* 1994; 193: 689-695
11. Verschuur EM, Homs MY, Steyerberg EW, Haringsma J, Wahab PJ, Kuipers EJ, Siersema PD. A new esophageal stent design (Niti-S stent) for the prevention of migration: a prospective study in 42 patients. *Gastrointest Endosc* 2006; 63: 134-140
12. Verschuur EM, Repici A, Kuipers EJ, Steyerberg EW, Siersema PD. New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. *Am J Gastroenterol* 2008; 103: 304-312
13. Kim ES, Jeon SW, Park SY, Cho CM, Tak WY, Kweon YO, Kim SK, Choi YH. Comparison of double-layered and covered Niti-S stents for palliation of malignant dysphagia. *J Gastroenterol Hepatol* 2009; 24: 114-119
14. Scheithauer W. Esophageal cancer: chemotherapy as palliative therapy. *Ann Oncol* 2004; 15 Suppl 4: iv97-1100
15. Ajani JA. Evolving chemotherapy for advanced gastric cancer. *Oncologist* 2005; 10 Suppl 3: 49-58
16. Hung AY, Canning CA, Patel KM, Holland JM, Kachnic LA. Radiation therapy for gastrointestinal cancer. *Hematol Oncol Clin North Am* 2006; 20: 287-321
17. Ogilvie AL, Drontfield MW, Ferguson R, Atkinson M. Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy. *Gut* 1982; 23: 1060-1067
18. Park JJ, Lee YC, Kim BK, Kim JH, Park JC, Kim YJ, Lee SK, Song SY, Chung JB. Long-term clinical outcomes of self-expanding metal stents for treatment of malignant gastro-esophageal junction obstructions and prognostic factors for stent patency: effects of anticancer treatments. *Dig Liver Dis* 2010; 42: 436-440
19. Vakil N, Morris AL, Marcon N, Segalin A, Peracchia A, Bethge N, Zuccaro G, Bosco JJ, Jones WF. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. *Am J Gastroenterol* 2001; 96: 1791-1796
20. Sabharwal T, Gulati MS, Fotiadis N, Doroudo R, Botha A, Mason R, Adam A. Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: proton pump inhibitor combination for prevention of post-stent reflux in patients with esophageal carcinoma involving the esophago-gastric junction. *J Gastroenterol Hepatol* 2008; 23: 723-728
21. Christie NA, Buenaventura PO, Fernando HC, Nguyen NT, Weigel TL, Ferson PF, Luketch JD. Results of expandable metal stents for malignant esophageal obstruction in 100 patients: short-term and long-term follow-up. *Ann Thorac Surg* 2001; 71: 1797-1801; discussion 1801-1802
22. Homs MY, Steyerberg EW, Kuipers EJ, van der Gaast A, Haringsma J, van Blankenstein M, Siersema PD. Causes and treatment of recurrent dysphagia after self-expanding metal stent placement for palliation of esophageal carcinoma. *Endoscopy* 2004; 36: 880-886
23. Dua KS, Kozarck R, Kim J, Evans J, Medda BK, Lang I, Horgan WJ, Shaker R. Self-expanding metal esophageal stent with anti-reflux mechanism. *Gastrointest Endosc* 2001; 53: 603-613
24. Harish G, Sandeep S, Madhukar K. Esophageal Stents. In: Kenneth L, Franco, Joe BP. Advanced Therapy in Thoracic Surgery. 2nd ed. Portland; BC Decker Pub, 2005; 526
25. Valbuena J. Palliation of gastroesophageal carcinoma with endoscopic insertion of a new antireflux prosthesis. *Gastrointest Endosc* 1984; 30: 241-243
26. Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, Hongo M, Ang TL, Holtmann G, Nandurkar S, Lin SR,
Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol 2008; 23: 8-22

Wong WM, Lai KC, Lau CP, Hu WH, Chen WH, Wong BC, Hui WM, Wong YH, Xia HH, Lam SK. Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain. Aliment Pharmacol Ther 2002; 16: 465-471

Baron TH. Minimizing endoscopic complications: endoluminal stents. Gastrointest Endosc Clin N Am 2007; 17: 83-104, vii

Laasch HU, Marriott A, Wilbraham L, Tunnah S, England RE, Martin DF. Effectiveness of open versus antireflux stents for palliation of distal esophageal carcinoma and prevention of symptomatic gastroesophageal reflux. Radiology 2002; 225: 359-365

Shim CS, Jung IS, Cheon YK, Ryu CB, Hong SJ, Kim JO, Cho JY, Lee JS, Lee MS, Kim BS. Management of malignant stricture of the esophagogastric junction with a newly designed self-expanding metal stent with an antireflux mechanism. Endoscopy 2005; 37: 335-339

Homs MY, Wahab PJ, Kuipers EJ, Steyerberg EW, Grool TA, Haringsma J, Siersema PD. Esophageal stents with antireflux valve for tumors of the distal esophagus and gastric cardia: a randomized trial. Gastrointest Endosc 2004; 60: 695-702

Schoppmeyer K, Golsong J, Schiefke I, Mössner J, Caca K. Antireflux stents for palliation of malignant esophagocardial stenosis. Dis Esophagus 2007; 20: 89-93

Sabharwal T, Morales JP, Irani FG, Adam A. Quality improvement guidelines for placement of esophageal stents. Cardiovasc Intervent Radiol 2005; 28: 284-288

S- Editor Cheng JX  L- Editor A  E- Editor Zhang DN